https://www.selleckchem.com/pr....oducts/Perifosine.ht
, agent of immunotherapy, and immunotherapy strategy in the intervention arm. This meta-analysis found no evidence of an association of sex, age (65 vs ≥65 years), or ECOG PS (0 vs ≥1) with cancer immunotherapy survival benefit. This finding suggests that the use of ICIs in advanced cancer should not be restricted to certain patients in sex, age, or ECOG PS categories. This meta-analysis found no evidence of an association of sex, age ( less then 65 vs ≥65 years), or ECOG PS (0 vs ≥1) with cancer immunotherapy survival benefit. T
Like
Comment
Share
